{"protocolSection":{"identificationModule":{"nctId":"NCT04105972","orgStudyIdInfo":{"id":"VX18-445-109"},"secondaryIdInfos":[{"id":"2019-001735-31","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Vertex Pharmaceuticals Incorporated","class":"INDUSTRY"},"briefTitle":"A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del","officialTitle":"A Phase 3b, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del"},"statusModule":{"statusVerifiedDate":"2021-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":true,"nctId":"NCT04058210","statusForNctId":"APPROVED_FOR_MARKETING"},"startDateStruct":{"date":"2019-10-03","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-07-24","type":"ACTUAL"},"completionDateStruct":{"date":"2020-07-24","type":"ACTUAL"},"studyFirstSubmitDate":"2019-09-24","studyFirstSubmitQcDate":"2019-09-24","studyFirstPostDateStruct":{"date":"2019-09-26","type":"ACTUAL"},"resultsFirstSubmitDate":"2021-07-23","resultsFirstSubmitQcDate":"2021-07-23","resultsFirstPostDateStruct":{"date":"2021-08-18","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-07-23","lastUpdatePostDateStruct":{"date":"2021-08-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Vertex Pharmaceuticals Incorporated","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study will evaluate the efficacy, safety, and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous for F508del."},"conditionsModule":{"conditions":["Cystic Fibrosis"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":176,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"TEZ/IVA","type":"ACTIVE_COMPARATOR","description":"Following TEZ/IVA run-in period of 4 weeks, participants received TEZ 100 milligrams (mg) once daily (qd)/IVA 150 mg every 12 hours (q12h) in the treatment period for 24 weeks.","interventionNames":["Drug: TEZ/IVA","Drug: IVA"]},{"label":"ELX/TEZ/IVA","type":"EXPERIMENTAL","description":"Following TEZ/IVA run-in period of 4 weeks, participants received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks.","interventionNames":["Drug: ELX/TEZ/IVA","Drug: IVA"]}],"interventions":[{"type":"DRUG","name":"ELX/TEZ/IVA","description":"FDC tablet for oral administration.","armGroupLabels":["ELX/TEZ/IVA"],"otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"type":"DRUG","name":"TEZ/IVA","description":"Fixed-dose combination (FDC) tablet for oral administration.","armGroupLabels":["TEZ/IVA"],"otherNames":["VX-661/VX-770","tezacaftor/ivacaftor"]},{"type":"DRUG","name":"IVA","description":"Mono tablet for oral administration.","armGroupLabels":["ELX/TEZ/IVA","TEZ/IVA"],"otherNames":["VX-770","ivacaftor"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Absolute Change in CF Questionnaire-Revised (CFQ-R) Respiratory Domain Score","description":"The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.","timeFrame":"From Baseline Through Week 24"}],"secondaryOutcomes":[{"measure":"Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.","timeFrame":"From Baseline Through Week 24"},{"measure":"Absolute Change in Sweat Chloride (SwCl)","description":"Sweat samples were collected using an approved collection device.","timeFrame":"From Baseline Through Week 24"},{"measure":"Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","timeFrame":"From Day 1 in the Treatment Period up to 28 Days After Last Dose of Study Drug or to the Completion of Study Participation Date, Whichever Occurs First (up to Week 28)"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Homozygous for the F508del mutation (F/F)\n* Forced expiratory volume in 1 second (FEV1) value ≥40% and ≤90% of predicted mean for age, sex, and height\n\nKey Exclusion Criteria:\n\n* Clinically significant cirrhosis with or without portal hypertension\n* Lung infection with organisms associated with a more rapid decline in pulmonary status\n* Solid organ or hematological transplantation\n\nOther protocol defined Inclusion/Exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"The Prince Charles Hospital","city":"Chermside","country":"Australia","geoPoint":{"lat":-27.38472,"lon":153.03062}},{"facility":"Institute for Respiratory Health","city":"Nedlands","country":"Australia","geoPoint":{"lat":-31.98184,"lon":115.8073}},{"facility":"Perth Children's Hospital","city":"Nedlands","country":"Australia","geoPoint":{"lat":-31.98184,"lon":115.8073}},{"facility":"John Hunter Hospital & Hunter Medical Research Institute and John Hunter Children's Hospital","city":"New Lambton","country":"Australia","geoPoint":{"lat":-32.95,"lon":151.68333}},{"facility":"The Royal Children's Hospital","city":"Parkville, VIC","country":"Australia"},{"facility":"Queensland Children's Hospital","city":"South Brisbane","country":"Australia","geoPoint":{"lat":-27.48034,"lon":153.02049}},{"facility":"Universitair Ziekenhuis Brussel - Campus Jette","city":"Brussels","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"UZ Antwerpen","city":"Edegem","country":"Belgium","geoPoint":{"lat":51.15662,"lon":4.44504}},{"facility":"Universitair Ziekenhuis Gent","city":"Gent","country":"Belgium","geoPoint":{"lat":51.05,"lon":3.71667}},{"facility":"Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg","city":"Leuven","country":"Belgium","geoPoint":{"lat":50.87959,"lon":4.70093}},{"facility":"Charite Paediatric Pulmonology Department","city":"Berlin","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Ruhrlandklinik Westdeutsches Lungenzentrum am Klinikum Essen","city":"Essen","country":"Germany","geoPoint":{"lat":51.45657,"lon":7.01228}},{"facility":"Universitatsklinikum Essen (AoR), Kinderklinik III, Abt. fur Pneumologie","city":"Essen","country":"Germany","geoPoint":{"lat":51.45657,"lon":7.01228}},{"facility":"Johann Wolfgang Goethe University","city":"Frankfurt","country":"Germany","geoPoint":{"lat":50.11552,"lon":8.68417}},{"facility":"Mukeviszidose-Zentrum am Universitatsklinikum Jena, Klinik fuer Kinder- und Jugendmedizin","city":"Jena","country":"Germany","geoPoint":{"lat":50.92878,"lon":11.5899}},{"facility":"Universitaetsklinkum Koeln, CF-Studienzentrum","city":"Koeln","country":"Germany","geoPoint":{"lat":50.93333,"lon":6.95}},{"facility":"Pneumologisches Studienzentrum Muenchen-West","city":"Muenchen","country":"Germany","geoPoint":{"lat":51.60698,"lon":13.31243}},{"facility":"Klinikum Innenstadt, University of Munich","city":"München","country":"Germany","geoPoint":{"lat":48.13743,"lon":11.57549}},{"facility":"Belfast City Hospital","city":"Belfast","country":"United Kingdom","geoPoint":{"lat":54.59682,"lon":-5.92541}},{"facility":"University Hospitals Birmingham NHS Foundation Trust","city":"Birmingham","country":"United Kingdom","geoPoint":{"lat":52.48142,"lon":-1.89983}},{"facility":"University Hospitals Bristol NHS Foundation Trust, Bristol Royal Hospital","city":"Bristol","country":"United Kingdom","geoPoint":{"lat":51.45523,"lon":-2.59665}},{"facility":"Papworth Hospital NHS Foundation Trust, Papworth Everard","city":"Cambridge","country":"United Kingdom","geoPoint":{"lat":52.2,"lon":0.11667}},{"facility":"Western General Hospital","city":"Edinburgh","country":"United Kingdom","geoPoint":{"lat":55.95206,"lon":-3.19648}},{"facility":"Royal Devon and Exeter NHS Foundation Trust, Royal Devon and Exeter Hospital","city":"Exeter","country":"United Kingdom","geoPoint":{"lat":50.7236,"lon":-3.52751}},{"facility":"Clinical Research Facility, Queen Elizabeth University Hospital","city":"Glasgow","country":"United Kingdom","geoPoint":{"lat":55.86515,"lon":-4.25763}},{"facility":"Leeds General Infirmary","city":"Leeds, West Yorkshire","country":"United Kingdom"},{"facility":"St. James University Hospital","city":"Leeds","country":"United Kingdom","geoPoint":{"lat":53.79648,"lon":-1.54785}},{"facility":"Alder Hey Children's Alder Hey Children's NHS Foundation Trust","city":"Liverpool","country":"United Kingdom","geoPoint":{"lat":53.41058,"lon":-2.97794}},{"facility":"Great Ormond Street Hospital for Sick Children","city":"London","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"London and St Bartholomew's Hospital","city":"London","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"The University Hospital of South Manchester","city":"Manchester","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}},{"facility":"The Newcastle upon Tyne Hospitals NHS Foundation Trust, The Royal Victoria Infirmary","city":"Newcastle Upon Tyne","country":"United Kingdom","geoPoint":{"lat":54.97328,"lon":-1.61396}},{"facility":"Nottingham University Hospitals NHS Trust, Queens Medical Center","city":"Nottingham","country":"United Kingdom","geoPoint":{"lat":52.9536,"lon":-1.15047}},{"facility":"All Wales Adult Cystic Fibrosis Centre, University Hospital Llandough","city":"Penarth","country":"United Kingdom","geoPoint":{"lat":51.4386,"lon":-3.17342}},{"facility":"Southampton General Hospital","city":"Southampton","country":"United Kingdom","geoPoint":{"lat":50.90395,"lon":-1.40428}}]},"referencesModule":{"references":[{"pmid":"34942085","type":"DERIVED","citation":"Sutharsan S, McKone EF, Downey DG, Duckers J, MacGregor G, Tullis E, Van Braeckel E, Wainwright CE, Watson D, Ahluwalia N, Bruinsma BG, Harris C, Lam AP, Lou Y, Moskowitz SM, Tian S, Yuan J, Waltz D, Mall MA; VX18-445-109 study group. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9. Epub 2021 Dec 20."},{"pmid":"33331662","type":"DERIVED","citation":"Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3."}]},"ipdSharingStatementModule":{"ipdSharing":"NO","description":"Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent research/clinical-trial-data-sharing."}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"This study was conducted in cystic fibrosis (CF) participants aged 12 years or older.","recruitmentDetails":"A total of 176 participants were enrolled in the study. Out of those 176 participants, 1 participant was randomized but not dosed in the treatment period. Therefore, results are presented for only 175 participants.","groups":[{"id":"FG000","title":"TEZ/IVA","description":"Following TEZ (tezacaftor)/IVA (ivacaftor) run-in period of 4 weeks, participants received TEZ 100 milligrams (mg) once daily (qd)/IVA 150 mg every 12 hours (q12h) in the treatment period for 24 weeks."},{"id":"FG001","title":"ELX/TEZ/IVA","description":"Following TEZ/IVA run-in period of 4 weeks, participants received ELX (elexacaftor) 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"88"},{"groupId":"FG001","numSubjects":"87"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"86"},{"groupId":"FG001","numSubjects":"86"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"TEZ/IVA","description":"Following TEZ/IVA run-in period of 4 weeks, participants received TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks."},{"id":"BG001","title":"ELX/TEZ/IVA","description":"Following TEZ/IVA run-in period of 4 weeks, participants received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"88"},{"groupId":"BG001","value":"87"},{"groupId":"BG002","value":"175"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"27.8","spread":"11.0"},{"groupId":"BG001","value":"27.9","spread":"11.8"},{"groupId":"BG002","value":"27.8","spread":"11.4"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"88"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"87"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"83"},{"groupId":"BG001","value":"85"},{"groupId":"BG002","value":"168"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}]},{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"88"},{"groupId":"BG001","value":"84"},{"groupId":"BG002","value":"172"}]}]},{"title":"White, Asian","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"CF Questionnaire-Revised (CFQ-R) Respiratory Domain Score","description":"The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"units on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"73.1","spread":"17.6"},{"groupId":"BG001","value":"71.2","spread":"19.6"},{"groupId":"BG002","value":"72.2","spread":"18.6"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Absolute Change in CF Questionnaire-Revised (CFQ-R) Respiratory Domain Score","description":"The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.","populationDescription":"Full analysis set (FAS) included all randomized participants who carried the intended CF transmembrane conductance regulator (CFTR) allele mutation and received at least 1 dose of study drug in treatment period.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"From Baseline Through Week 24","groups":[{"id":"OG000","title":"TEZ/IVA","description":"Following TEZ/IVA run-in period of 4 weeks, participants received TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks."},{"id":"OG001","title":"ELX/TEZ/IVA","description":"Following TEZ/IVA run-in period of 4 weeks, participants received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"87"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"1.5"},{"groupId":"OG001","value":"17.1","spread":"1.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"< 0.0001","statisticalMethod":"Mixed-effects Model for Repeated Measure","paramType":"Least Squares (LS) Mean Difference","paramValue":"15.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"11.7","ciUpperLimit":"20.1"}]},{"type":"SECONDARY","title":"Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.","populationDescription":"FAS.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"percentage points","timeFrame":"From Baseline Through Week 24","groups":[{"id":"OG000","title":"TEZ/IVA","description":"Following TEZ/IVA run-in period of 4 weeks, participants received TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks."},{"id":"OG001","title":"ELX/TEZ/IVA","description":"Following TEZ/IVA run-in period of 4 weeks, participants received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"87"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"0.7"},{"groupId":"OG001","value":"11.2","spread":"0.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Mixed-effects Model for Repeated Measure","paramType":"LS Mean Difference","paramValue":"10.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"8.2","ciUpperLimit":"12.1"}]},{"type":"SECONDARY","title":"Absolute Change in Sweat Chloride (SwCl)","description":"Sweat samples were collected using an approved collection device.","populationDescription":"FAS.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"millimole per liter (mmol/L)","timeFrame":"From Baseline Through Week 24","groups":[{"id":"OG000","title":"TEZ/IVA","description":"Following TEZ/IVA run-in period of 4 weeks, participants received TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks."},{"id":"OG001","title":"ELX/TEZ/IVA","description":"Following TEZ/IVA run-in period of 4 weeks, participants received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"87"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"1.2"},{"groupId":"OG001","value":"-46.2","spread":"1.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"LS Mean Difference","paramValue":"-42.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-46.2","ciUpperLimit":"-39.3"}]},{"type":"SECONDARY","title":"Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","populationDescription":"Safety set included all participants who received at least 1 dose of study drug in the treatment period.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"From Day 1 in the Treatment Period up to 28 Days After Last Dose of Study Drug or to the Completion of Study Participation Date, Whichever Occurs First (up to Week 28)","groups":[{"id":"OG000","title":"TEZ/IVA","description":"Following TEZ/IVA run-in period of 4 weeks, participants received TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks."},{"id":"OG001","title":"ELX/TEZ/IVA","description":"Following TEZ/IVA run-in period of 4 weeks, participants received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"87"}]}],"classes":[{"title":"Participants With TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"77"}]}]},{"title":"Participants With SAEs","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"5"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From Day 1 in the Treatment Period up to 28 Days After Last Dose of Study Drug or to the Completion of Study Participation Date, Whichever Occurs First (up to Week 28)","eventGroups":[{"id":"EG000","title":"TEZ/IVA","description":"Following TEZ/IVA run-in period of 4 weeks, participants received TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks.","deathsNumAffected":0,"deathsNumAtRisk":88,"seriousNumAffected":14,"seriousNumAtRisk":88,"otherNumAffected":72,"otherNumAtRisk":88},{"id":"EG001","title":"ELX/TEZ/IVA","description":"Following TEZ/IVA run-in period of 4 weeks, participants received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks.","deathsNumAffected":0,"deathsNumAtRisk":87,"seriousNumAffected":5,"seriousNumAtRisk":87,"otherNumAffected":59,"otherNumAtRisk":87}],"seriousEvents":[{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":88},{"groupId":"EG001","numAffected":1,"numAtRisk":87}]},{"term":"Extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":88},{"groupId":"EG001","numAffected":0,"numAtRisk":87}]},{"term":"Distal intestinal obstruction syndrome","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":88},{"groupId":"EG001","numAffected":0,"numAtRisk":87}]},{"term":"Infective pulmonary exacerbation of cystic fibrosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":88},{"groupId":"EG001","numAffected":1,"numAtRisk":87}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":88},{"groupId":"EG001","numAffected":0,"numAtRisk":87}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":88},{"groupId":"EG001","numAffected":1,"numAtRisk":87}]},{"term":"Type 3 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":88},{"groupId":"EG001","numAffected":1,"numAtRisk":87}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":88},{"groupId":"EG001","numAffected":1,"numAtRisk":87}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":88},{"groupId":"EG001","numAffected":1,"numAtRisk":87}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":88},{"groupId":"EG001","numAffected":0,"numAtRisk":87}]},{"term":"Obsessive-compulsive disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":88},{"groupId":"EG001","numAffected":0,"numAtRisk":87}]},{"term":"Psychotic disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":88},{"groupId":"EG001","numAffected":0,"numAtRisk":87}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":88},{"groupId":"EG001","numAffected":1,"numAtRisk":87}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":88},{"groupId":"EG001","numAffected":0,"numAtRisk":87}]}],"otherEvents":[{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":88},{"groupId":"EG001","numAffected":4,"numAtRisk":87}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":88},{"groupId":"EG001","numAffected":8,"numAtRisk":87}]},{"term":"Infective pulmonary exacerbation of cystic fibrosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":32,"numAtRisk":88},{"groupId":"EG001","numAffected":10,"numAtRisk":87}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":88},{"groupId":"EG001","numAffected":17,"numAtRisk":87}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":88},{"groupId":"EG001","numAffected":9,"numAtRisk":87}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":88},{"groupId":"EG001","numAffected":6,"numAtRisk":87}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":88},{"groupId":"EG001","numAffected":5,"numAtRisk":87}]},{"term":"Bacterial test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":88},{"groupId":"EG001","numAffected":1,"numAtRisk":87}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":88},{"groupId":"EG001","numAffected":25,"numAtRisk":87}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":88},{"groupId":"EG001","numAffected":11,"numAtRisk":87}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":88},{"groupId":"EG001","numAffected":3,"numAtRisk":87}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":88},{"groupId":"EG001","numAffected":6,"numAtRisk":87}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":88},{"groupId":"EG001","numAffected":11,"numAtRisk":87}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":88},{"groupId":"EG001","numAffected":8,"numAtRisk":87}]},{"term":"Sputum increased","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":88},{"groupId":"EG001","numAffected":10,"numAtRisk":87}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":88},{"groupId":"EG001","numAffected":7,"numAtRisk":87}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"pointOfContact":{"title":"Medical Monitor","organization":"Vertex Pharmaceuticals Incorporated","email":"medicalinfo@vrtx.com","phone":"617-341-6777"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2019-05-30","uploadDate":"2021-06-24T04:16","filename":"Prot_000.pdf","size":736714},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2020-08-02","uploadDate":"2021-06-24T04:17","filename":"SAP_001.pdf","size":5330893}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-04-09"},"conditionBrowseModule":{"meshes":[{"id":"D003550","term":"Cystic Fibrosis"},{"id":"D005355","term":"Fibrosis"}],"ancestors":[{"id":"D010335","term":"Pathologic Processes"},{"id":"D010182","term":"Pancreatic Diseases"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D030342","term":"Genetic Diseases, Inborn"},{"id":"D007232","term":"Infant, Newborn, Diseases"}],"browseLeaves":[{"id":"M8485","name":"Fibrosis","asFound":"Fibrosis","relevance":"HIGH"},{"id":"M6755","name":"Cystic Fibrosis","asFound":"Cystic Fibrosis","relevance":"HIGH"},{"id":"M13102","name":"Pancreatic Diseases","relevance":"LOW"},{"id":"M8883","name":"Gastrointestinal Diseases","relevance":"LOW"},{"id":"M7255","name":"Digestive System Diseases","relevance":"LOW"},{"id":"M11168","name":"Lung Diseases","relevance":"LOW"},{"id":"M14977","name":"Respiratory Tract Diseases","relevance":"LOW"},{"id":"M23686","name":"Genetic Diseases, Inborn","relevance":"LOW"},{"id":"M10276","name":"Infant, Newborn, Diseases","relevance":"LOW"},{"id":"T1710","name":"Cystic Fibrosis","asFound":"Cystic Fibrosis","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC06","name":"Digestive System Diseases"},{"abbrev":"BC08","name":"Respiratory Tract (Lung and Bronchial) Diseases"},{"abbrev":"BC16","name":"Diseases and Abnormalities at or Before Birth"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C545203","term":"Ivacaftor"},{"id":"C000629074","term":"Elexacaftor"}],"ancestors":[{"id":"D065101","term":"Chloride Channel Agonists"},{"id":"D049990","term":"Membrane Transport Modulators"},{"id":"D045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M250281","name":"Ivacaftor","asFound":"Dextrose","relevance":"HIGH"},{"id":"M76784","name":"Elexacaftor","asFound":"Morning after","relevance":"HIGH"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true}
